Fig. 2From: A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancerMean percentage changes of DCE-MRI parameters at 1Â h, 24Â h, and 21Â days compared with baseline valuesBack to article page